Your session is about to expire
← Back to Search
HSPPC-96 for Glioblastoma
Study Summary
This trial is testing whether a vaccine made from a person's own tumor tissue, with or without bevacizumab, is effective in treating recurrent glioblastoma multiforme.
- Glioblastoma (GBM)
- Gliosarcoma
- Brain Tumor
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any other scientific papers which mention the HSPPC-96 protein?
"At the moment, there are 377 different clinical trials studying HSPPC-96. Out of those, 99 are in Phase 3. Even though most of the research for HSPPC-96 is conducted in Taibei, Taiwan, there are a total of 18929 locations running studies on this potential treatment."
What are some of the risks associated with taking HSPPC-96?
"Since this is a Phase 2 trial, there is only preliminary evidence to support the safety of HSPPC-96. It received a score of 2."
Why is HSPPC-96 often recommended to patients?
"HSPPC-96 is most commonly used as a treatment for cancer. It can also be used to treat multiple other conditions such as recurrent platinum sensitive primary peritoneal cancer, stage iv epithelial ovarian cancer following initial surgical resection, and locally advanced nonsquamous non-small cell lung cancer."
Are patients currently being accepted for this trial?
"The clinical trial mentioned is not currently seeking patients, as seen on clinicaltrials.gov. This research was initially posted on May 1st, 2013 and last updated on August 16th, 2021. Even though this study isn't recruiting, there are 1824 other trials that are."
How many people can join this trial at most?
"This particular clinical trial is not currently enrolling patients. However, 377 other studies posted on the website are actively looking for participants with gliosarcoma. For context, 1447 studies are currently recruiting across all topics."
Share this study with friends
Copy Link
Messenger